Key Highlights
- Valion Bio shares closed down 29% at $0.37.
- Valion Bio and Sheba Medical Center finalized an agreement to fund and execute a clinical trial of Entolimod.
- The study will involve up to 10 irradiated oncology patients.
- The trial evaluates Entolimod for radiation-induced neutropenia.
Valion Bio (NASDAQ: VBIO) shares closed down 29% at $0.37 even after the company and Sheba Medical Center finalized an agreement to fund and execute a clinical trial of Entolimod.
What Happened
The study, which will involve up to 10 irradiated oncology patients, is designed to evaluate Entolimod as a treatment for radiation-induced neutropenia.
The partnership establishes what the company describes as a capital-efficient expansion of Valion's oncology-supportive pipeline, complementing its primary medical countermeasure program for Acute Radiation Syndrome.
Market Reaction
Shares fell 29% to close at $0.37 despite the new trial agreement, a decline that stands in contrast to the positive framing of the Sheba partnership in the company's disclosure.
The disclosed information does not specify a reason for the share price decline beyond the trial announcement itself.
Outlook
The trial's small scale, up to 10 irradiated oncology patients, positions it as an early, capital-efficient step in Valion's oncology-supportive pipeline, according to the disclosed information.
What did Valion Bio and Sheba Medical Center agree to?
They finalized an agreement to fund and execute a clinical trial of Entolimod involving up to 10 irradiated oncology patients.
What is Entolimod being tested for in this trial?
The trial evaluates Entolimod as a treatment for radiation-induced neutropenia.
Why did Valion Bio shares fall 29% despite the new trial deal?
The disclosed information does not specify a reason for the decline beyond the announcement itself.






Please wait processing your request...